Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 19, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of specific share transactions and does not contain financial performance data.
Material Changes and Transactions
The filing details the following transactions executed by employee trusts on behalf of plan participants:
- March 14, 2007: The GSK Trust sold 69,039 Ordinary Shares at GBP 14.21 per share and transferred 130,571 Ordinary Shares to Performance Share Plan participants.
- March 15, 2007: The GSK Trust transferred 6,575 Ordinary Shares to the SmithKline Beecham Employee Share Option Plan 1991. The GSK US Trust sold 23,348 ADRs at $54.71 per ADR and transferred 38,114 ADRs to the Share Value Plan.
- March 16, 2007: The GSK US Trust sold 49,890 ADRs at $54.86 per ADR and transferred 98,458 ADRs to the Performance Share Plan.
Management Commentary and Risks
The filing notes that Directors Dr. J-P Garnier, Dr. M M Slaoui, and Mr. J S Heslop hold interests in the GSK Trust, while Dr. J-P Garnier and Dr. M M Slaoui hold interests in the GSK US Trust, in the same capacity as other employees. The transactions were notified in accordance with Disclosure Rule 3.1.4R(1)(b). No specific risks, contingencies, or unusual items beyond the standard disclosure of director interests are mentioned.
Investor Verification Checklist
- Verify the total volume of shares and ADRs sold versus transferred to understand net dilution or retention.
- Confirm the specific share prices (GBP 14.21 and USD 54.71/54.86) against market data for the transaction dates.
- Review the full list of directors with interests in the GSK Trust and GSK US Trust to assess potential conflicts of interest.
- Note that this filing contains no financial performance data; refer to Form 20-F for fiscal results.